Cell Line and Membrane Market Size, Share, Competitive Landscape and Trend Analysis Report by Products, by Source, by Type, by End User : Global Opportunity Analysis and Industry Forecast, 2021-2031

Cell Line And Membrane Market Research, 2031

The global Cell Line and Membrane Market size was valued at $4.5 billion in 2021, and is projected to reach $10.6 billion by 2031, growing at a CAGR of 8.8% from 2022 to 2031. Cell line is a general term that applies to a defined population of cells that can be maintained in culture for an extended period of time, retaining stability of certain phenotypes and functions. Cell lines are usually clonal, meaning that the entire population originated from a single common ancestor cell. A cell line is a permanently established cell culture that will multiply indefinitely given appropriate fresh medium and space and is frequently used to investigate biological processes in place of primary cells. Cell line development is the process of creating stable cell lines for use in a variety of applications, including the creation of biologics (recombinant proteins and monoclonal antibodies), drug screening, and gene functional investigations. Transfection, selection, and single-cell cloning are all part of the cell line generation process. Distinct types of cells are used to create different cell lines. Cell lines allow for gradual changes in cell structure, physiology, and genetic makeup in a controlled setting

The key factors that drive the Cell Line and Membrane Market growth are rises in the prevalence of cancer and chronic diseases. Moreover, an increase in the geriatric population, an increase in the adoption of regenerative medicines, and a surge in investments in R&D by pharmaceutical and biotechnology companies propel the growth of the market. Moreover, the market is expected to experience growth during the forecast period owing to the rise in development and demand for monoclonal antibodies around the globe, the rise in vaccine production, and technological innovations in cell lines and the membrane. For instance, in April 2020, CEVEC Pharmaceuticals GmbH announced the launch of the ELEVECTA platform, which will produce stable cell lines for AAV (Adeno-associated viral) vector for gene therapy. The technology increases the production of viral vectors, used in the production of monoclonal antibodies and recombinant proteins.

However, a strict regulatory framework coupled with the time-consuming process for the development of stable lines might restrain the growth of the market. Whereas, low-income countries lacking access to basic healthcare and the increase in the risk of pandemic and communicable diseases provides lucrative Cell Line and Membrane Market opportunity for the key player operating in the market. 

Cell Line and Membrane market segmentation

The global Cell Line and Membrane Market size was valued at $4.5 billion in 2021 and is projected to reach $10.6 billion by 2031, growing at a CAGR of 8.8% from 2022 to 2031. In addition, the market is segmented on the basis of product, source, type, end user, and region. By product, the market is segmented into media and reagents, equipment and accessories, and consumables. By source, it is segmented into mammalian cell lines and non-mammalian cell lines. By type, the market is segmented into recombinant cell type, hybridomas, continuous cell line, and primary cell line. By end user the market is segmented into biotech companies, academic and research institutes, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Product Segment review

By product, the Cell Line and Membrane Market are segmented into media & reagents, equipment and accessories & consumables. In 2021, the media and reagents segment accounted for the largest share of the market. The dominance of this segment can be attributed to the rise in the prevalence of cancer and chronic disease, and rise in number of R&D activities across the world, and increasing product approval and new product launches. The equipment segment is anticipated to grow at a significant rate during the forecast period. Owing to increase in demand of technologically advanced equipment for the development of cell line and membranes.

Source Segment review

By source, the Cell Membrane Market are segmented into mammalian cell line and non-mammalian cell line. In 2021, the mammalian cell line segment accounted for the largest share of the market. The dominance of this segment can be attributed to the rise in the demand of recombinant protein development through the mammalian cell. The non-mammalian segment is anticipated to grow at a significant rate during the forecast period. Owing to increase in adoption of regenerative medicines, rise in prevalence of cancer across the globe, and a surge in investments in R&D by pharmaceutical and biotechnology companies.

Type Segment Review

By application, the cell line and membrane market is segmented into recombinant cell type, hybridomas, continuous cell line and primary cell line, the recombinant cell line segment exhibited the highest growth in 2021, and is anticipated to lead during the forecast period, owing to the rise in the demand of recombinant cell line which owes a great deal to technological advancement in expression vector design, cell line engineering and clone screening are the key factors that drive the growth of market during the forecast period. The primary cell line segment is anticipated to grow at a significant rate during the forecast period.

End User Segment Review

By end user the cell line and membrane market is segmented into biotechnology and pharmaceutical companies, academic and research institutes and others, the biotechnology and pharmaceutical industries segment exhibited the highest growth in 2021, and is anticipated to lead during the forecast period, owing to the rise in the demand of biotherapeutic and biosimilar drugs, increase in geriatric population and rise in the prevalence of cancer are the key factors that drives the growth of market. 

The academic & research institutes segment is expected to witness considerable growth in the cell line and membrane market during the forecast period, owing to an increase in the number of R&D activities as tissue engineering has evolved into the broader area of regenerative medicine, which focuses on developing clinical therapies for the maintenance, repair, replacement, and enhancement of biological function using cell engineering hence, provide lucrative opportunities for the researcher to conduct various types of R&D activities on the cell line.

Region Segment Review

Region-wise, the Cell Line Market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for a majority of the Cell Line and Membrane market share in 2021 and is anticipated to remain dominant during the forecast period. Owing to the increase in the healthcare expenditure on in this region and the rise in the prevalence of cancer due to an aging, unhealthy lifestyle. Increase in demand of cell lines for the development of therapeutic monoclonal antibodies and novel antibodies. Moreover, the presence of major players in the country for the development of cell lines boosts market growth.

Asia-Pacific was the second largest contributor to the cell line and membrane market in 2021, and is expected to register the fastest CAGR during the forecast period, owing to rise in the prevalence of chronic diseases, an increase in the geriatric population and an emerging economy.

The key players that operate in the cell line and membrane market are Advanced Instruments LLC, AGC Biologics, Cytiva Lifesciences, Sartorius Cellgenix Gmbh, Premas Biotech, Selexis SA, Lonza, Samsung Biologics, PromoCell, Thermofisher Scientific Inc, Imegenex India Pvt. Ltd., ProBioGen

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cell line and membrane market analysis from 2021 to 2031 to identify the prevailing cell line and membrane market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the cell line and membrane market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global cell line and membrane market trends, key players, market segments, application areas, and market growth strategies.

  Cell Line and Membrane Market Report Highlights

Aspects	Details
Market Size By 2031	USD 10.6 billion
Growth Rate	CAGR of 8.8%
Forecast period	2021 - 2031
Report Pages	346
By Products	Media and Reagents Type Serum Media Reagents Equipments Type Biosafety Cabinets Cell Counters and Viability Systems Incubators Centrifuges Bioreactors Storage Equipment Others Accessories and Consumables
By Source	Non Mammalian Cell Line Type Insects Amphibians Mammalian Cell Line
By Type	Hybridomas Continuous cell lines Recombinant cell lines Primary cell lines
By End User	Biotechnology and Pharmaceutical Industries Academic and Research Institutes Others
By Region	North America  (U.S., Canada, Mexico) Europe  (Germany, France, UK, Italy, Spain, Rest Of Europe) Asia-Pacific  (Japan, China, Australia, India, South Korea, Rest Of Asia-Pacific) LAMEA  (Brazil, Saudi Arabia, South Africa, Rest Of LAMEA)
Key Market Players	Cellgenix Gmbh, Advanced Instruments LLC, ProBioGen, Lonza, Samsung Biologics, AGC Biologics, Selexis SA, Sartorius, PromoCell, Cytiva Lifesciences, Thermofisher Scientific Inc, Premas Biotech

Analyst Review

This section provides various opinions of top-level CXOs in the cell line and membrane market. In accordance to several interviews conducted, the cell line and membrane market is expected to witness a significant growth in the future, owing to rise in geriatric population and increase in prevalence of cancer and various other chronic diseases.

According to the perspectives of CXOs, cell line and membrane market is expected to witness a steady growth in the future owing to rise in geriatric population, increase in adoption of regenerative medicines, and surge in investments in R&D by pharmaceutical and biotechnology companies. In addition, rise in technological advancement and surge in development & demand for monoclonal antibodies around the globe propel the growth of the market. However, a strict regulatory framework coupled with time-consuming process for the development of stable lines might hamper the growth of the market up to some extent during the forecast period.

On the contrary, growth in demand for novel drug therapies and increase in the risk of pandemic & communicable diseases are expected to provide opportunities for the growth of the cell line and membrane market in future.

Further, North America is expected to witness highest growth, in terms of revenue, due to presence of advanced healthcare facilities provided by government & private authorities, rise in R&D facilities for the approval & development of novel drug therapies in the region.

Asia-Pacific was the second largest contributor to the market in 2021, and is expected to register the fastest CAGR during the forecast period

Author Name(s) : Vikita Thakur | Roshan Deshmukh

Related Tags

• Stem Cell Research
• Bioproduction
• Drug Discovery